文献速递银屑病与炎症性皮肤病

IL-23与IL-12/23抑制剂预防银屑病患者偶发银屑病关节炎的真实世界比较

Interleukin 23 versus interleukin 12/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network.
PubMed 文献 · J Am Acad Dermatol · 2024-07-28

本研究基于TriNetX全球协作网络开展回顾性队列研究,纳入接受IL-23抑制剂(n=2273)或IL-12/23抑制剂(n=2995)治疗的成人银屑病患者,经倾向评分匹配后比较银屑病关节炎累积发病率。结论提示IL-23抑制剂与IL-12/23抑制剂在预防银屑病关节炎方面疗效相当,但IL-23抑制剂组风险数值上更低。

要点

  • IL-23抑制剂与IL-12/23抑制剂在预防银屑病关节炎方面无显著差异。
  • IL-23抑制剂组银屑病关节炎风险数值上低于IL-12/23抑制剂组。
  • 两组关节病性银屑病累积发病率经Kaplan-Meier估计相似。

核心结论

  • IL-23抑制剂与IL-12/23抑制剂在银屑病患者中预防银屑病关节炎无显著差异,但IL-23抑制剂组风险数值上更低。

研究设计与样本

  • 回顾性队列研究,利用TriNetX全球协作网络数据,纳入成人银屑病患者,接受IL-23抑制剂(n=2273)或IL-12/23抑制剂(n=2995)治疗,经倾向评分匹配。

主要发现

  • Kaplan-Meier估计证实两组关节病性银屑病累积发病率在研究期间相似。

临床怎么用

  • 临床选择IL-23或IL-12/23抑制剂时,两者在预防银屑病关节炎方面疗效相当,可综合考虑其他因素。

局限性

  • 需要长期随访研究以进一步了解这些白细胞介素抑制剂的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Managing psoriasis (PsO) and its comorbidities, particularly psoriatic arthritis, often involves using interleukin (IL)-23 and IL-12/23 inhibitors. However, the comparative risk of these treatments still needs to be explored. OBJECTIVE: This study evaluates the risk of developing psoriatic arthritis in patients treated with IL-23 inhibitors compared to IL-12/23 inhibitors. METHODS: This retrospective cohort study utilized data from the TriNetX, including adult patients diagnosed with PsO. Patients with IL-23 or IL-12/23 inhibitors treatment were included and propensity score matched. The primary outcome was the incidence of psoriatic arthritis (PsA), analyzed using a Cox regression hazard model and Kaplan-Meier estimates. RESULTS: The study included matched cohorts of patients treated with IL-23 inhibitors (n = 2273) and IL-12/23 inhibitors (n = 2995). Cox regression analysis revealed no significant difference in the cumulative incidence of PsA between the IL-23i and IL-12/23i cohorts (P = .812). Kaplan-Meier estimates confirmed similar cumulative incidences of arthropathic PsO in both cohorts over the study period. LIMITATION: Long-term follow-up studies are required to understand more of the effects of these interleukin inhibitors. CONCLUSION: No significant difference but a numerically lower risk of psoriatic arthritis in PsO patients treated with IL-23 inhibitors than with IL-12/23 inhibitors was found, underscoring their comparable efficacy in PsO management and follow-up.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Tsai SHL, Yang CY, Huo AP, et al. Interleukin 23 versus interleukin 12/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network. J Am Acad Dermatol. 2024. PMID: 39079603. doi:10.1016/j.jaad.2024.07.1473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。